| Officer | Age | In this role | Source |
|---|---|---|---|
|
Tim Knotnerus
Also a director
Chief Executive Officer and Executive Director
|
43 |
Since 2019
7 years
|
|
|
Pierre Thadee Victor Kemula
Chief Financial Officer
Title from the Form 4 dated Oct 6, 2026
|
Not stated | Not stated | |
|
Philippe Wiesel
Chief Medical Officer
|
Not stated |
Since 2021
5 years
|
|
|
Andrea Sáez
Chief Development Officer
|
Not stated |
Since 2023
3 years
|
|
|
Paul van der Horst
Chief Business Officer
|
Not stated |
Since 2021
5 years
|
|
|
Ellen Lefever
General Counsel
|
Not stated |
Since 2021
5 years
|
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Related-party transactions come from the company’s proxy statement. AgomAb Therapeutics NV has not filed one with the SEC.
Loading...